PLAINSBORO, N.J., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the introduction of the next-generation Licox® Brain Tissue Oxygen Monitoring System. The Licox system continually monitors brain oxygen partial pressure (PtO2) in patients who have sustained a traumatic brain injury or cerebral vascular event. The Licox system provides clinicians with early warning of hypoxic events, allowing more timely intervention to restore oxygen delivery to the vital tissues of the brain. It is the most widely studied and documented direct cerebral tissue oxygen monitoring device available to the clinician, and has been widely used in neurocritical care since it was launched in the United States in 2001. The new Licox system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and will be featured at the Congress of Neurological Surgeons (CNS) annual meeting, October 19 - 23, 2013, in San Francisco, California.